How it works:
Lenalidomide modulates the immune system, inhibits tumour cell proliferation, and reduces angiogenesis. It enhances T-cell and NK-cell activity and is less toxic than thalidomide. The 5mg dose is ideal for elderly patients, maintenance therapy, or when lower toxicity is required.
Recommended for:
Patients with multiple myeloma
Individuals diagnosed with MDS
Maintenance therapy post-stem cell transplantation
Patients intolerant to higher doses of lenalidomide
Elderly or renally impaired individuals (as per medical advice)
Multiple myeloma
Myelodysplastic syndromes (incl. with 5q deletion)
Maintenance therapy after bone marrow transplant
Select lymphoproliferative disorders
Taken orally once daily at the same time, with water. Dosage is determined by the treating oncologist based on diagnosis, laboratory data, and patient condition. Blood counts and liver function must be monitored regularly during treatment.
Hypersensitivity to lenalidomide
Pregnancy and breastfeeding
Severe hepatic or renal insufficiency
Children and adolescents
High thromboembolism risk
Neutropenia, anaemia
Nausea, constipation
Fatigue
Allergic skin reactions, rashes
Risk of thromboembolism
Insomnia, headache
